Myeloma bone disease: Progress in pathogenesis

被引:6
|
作者
Xi, Hao [1 ]
An, Ran [1 ]
Li, Lu [1 ]
Wang, Gang [2 ]
Tao, Yi [3 ]
Gao, Lu [2 ]
机构
[1] Second Mil Med Univ, Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China
[2] Second Mil Med Univ, Dept Physiol, 800 Xiangyin Rd, Shanghai 200433, Peoples R China
[3] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Hematol, Shanghai, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
Myeloma bone disease; Osteoblast; Osteoclast; Osteoclast cell activating factor; Osteoblast cell inactivating factor; MULTIPLE-MYELOMA; OSTEOCLAST FORMATION; GROWTH-FACTOR; IN-VITRO; OSTEOBLAST DIFFERENTIATION; CELL-PROLIFERATION; TUMOR BURDEN; INHIBITION; ACTIVATION; EXPRESSION;
D O I
10.1016/j.pbiomolbio.2016.08.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myeloma bone disease (MBD) is one of the most serious complications of multiple myeloma (MM) and the most severe cause of MM morbidity. Dysregulation of osteoblast and osteoclast cells plays key roles in MBD. In the bone marrow microenvironment, myeloma cells, osteoblasts, osteoclasts and bone marrow stromal cells can secrete multiple cytokines, categorized as osteoclast cell activating factors (OAFS) and osteoblast cell inactivating factors, which have been discovered to participate in bone metabolism and contribute to the pathogenesis of MBD. Several signaling pathways related to these cytokines were also revealed in the MBD pathogenesis. To better understand the pathogenesis of MBD and therefore the potential therapeutic targets of this disease, we will summarize recent study progress in the factors and underlying signaling pathways involved in the occurrence and development of MBD. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:149 / 155
页数:7
相关论文
共 50 条
  • [41] Bone disease in multiple myeloma
    Hjertner, Oyvind
    Standal, Therese
    Borset, Magne
    Sundan, Anders
    Waage, Anders
    MEDICAL ONCOLOGY, 2006, 23 (04) : 431 - 441
  • [42] Treatment for myeloma bone disease
    Yeh, Howard S.
    Berenson, James R.
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6279S - 6284S
  • [43] Pathogenesis of Paget Disease of Bone
    Ralston, Stuart H.
    Layfield, Rob
    CALCIFIED TISSUE INTERNATIONAL, 2012, 91 (02) : 97 - 113
  • [44] Pathogenesis of Paget Disease of Bone
    Stuart H. Ralston
    Rob Layfield
    Calcified Tissue International, 2012, 91 : 97 - 113
  • [45] Multiple Myeloma: Molecular Pathogenesis and Disease Evolution
    Heider, Michael
    Nickel, Katharina
    Hoegner, Marion
    Bassermann, Florian
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (12) : 672 - 680
  • [46] Role of intensive therapy in myeloma and myeloma bone disease
    Barlogie, B
    Walker, R
    Rasmussen, E
    Anaissie, E
    Tricot, G
    Shaughnessy, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 : P14 - P14
  • [47] Repeat expansion disease: progress and puzzles in disease pathogenesis
    Albert R. La Spada
    J. Paul Taylor
    Nature Reviews Genetics, 2010, 11 : 247 - 258
  • [48] Repeat expansion disease: progress and puzzles in disease pathogenesis
    La Spada, Albert R.
    Taylor, J. Paul
    NATURE REVIEWS GENETICS, 2010, 11 (04) : 247 - 258
  • [49] Bone Disease From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: Pathogenesis, Interventions, and Future Opportunities
    Minter, Alex R.
    Simpson, Haley
    Weiss, Brendan M.
    Landgren, Ola
    SEMINARS IN HEMATOLOGY, 2011, 48 (01) : 55 - 65
  • [50] BONE BIOMARKERS ARE USEFUL IN MONITORING MYELOMA BONE DISEASE AND AS EARLY PREDICTOR FOR RELAPSE DISEASE IN MULTIPLE MYELOMA
    Ting, K.
    Hameed, A.
    Brady, J.
    Carke, C.
    Justine, M.
    Dowling, P.
    Clynes, M.
    O'Gorman, P.
    HAEMATOLOGICA, 2013, 98 : 334 - 335